[BC 105 in migraine].
D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000009:adverse effects / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008784:Methysergide / Q000009:adverse effects / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D012702:Serotonin Antagonists; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
D003508:Cycloheptanes; D006634:Histamine H1 Antagonists; D010880:Piperidines; D010919:Placebos; D012702:Serotonin Antagonists; D013876:Thiophenes; D008784:Methysergide
BC 105 en jaquecas.